Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. latamerica
  4. biomedical developers
Show results for
Products
Services

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Biomedical Developers Articles & Analysis

52 news found

Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market

Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market

Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. ...

ByBened Biomedical Co., Ltd.


BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study

BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study

Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today preliminary results from a Biomedical Advanced Research and Development Authority (BARDA)-supported effort to develop an intranasal formulation of its drug candidate, LMN-301. ...

ByLumen Bioscience, Inc.


Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium ...

ByLumen Bioscience, Inc.


SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...

BySIGA Technologies, Inc.


ARAI-2PAM Barda Procurement Award

ARAI-2PAM Barda Procurement Award

Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. ...

ByAktiv Pharma Group, Inc


Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001

Enalare Therapeutics Receives an Additional Award Worth Up to $50 Million From BARDA, Expanding Its Partnership in Development of ENA-001

The Funding Supports Development of an Intramuscular ENA-001 From Pre-Clinical Toxicology Through Filing for Approval in the United States Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care diseases and community medical threats, announced today that it ...

ByEnalare Therapeutics Inc.


Celdara Medical Announces Funding for Alzheimer’s-Focused Fellowship Opportunities

Celdara Medical Announces Funding for Alzheimer’s-Focused Fellowship Opportunities

This project builds on Celdara Medical’s Biomedical Industry Fellowship that promotes entrepreneurial skills development in biotech for senior graduate students and postdoctoral fellows. The A-CHEF program will train rising scientists in biomedical entrepreneurship and drug development. Through formal mentorship from the ...

ByCeldara Medical, LLC


Enalare Therapeutics Receives a National Institutes of Health (NIH) Grant Award

Enalare Therapeutics Receives a National Institutes of Health (NIH) Grant Award

"We are honored to receive this important grant award," stated Joseph Pergolizzi M.D., Chief Research and Development Officer of Enalare. "This funding supports further development of ENA001, which we believe has the potential to improve the standard of care in treating drug-induced respiratory depression with its unique mechanism of action as an agnostic ...

ByEnalare Therapeutics Inc.


Locus Biosciences Announces $35 Million Financing

Locus Biosciences Announces $35 Million Financing

Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision medicine for UTIs mid-2022 Locus Biosciences, Inc. ...

ByLocus Biosciences, Inc.


OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

Zerhouni brings extensive experience in academia, government and industry as a leading authority on emerging trends and issues in medical care and biomedical research and development. A physician scientist with an academic background in imaging and biomedical engineering, Dr. ...

ByOPKO Health, Inc.


Berkshire Biomedical, Developers of COPA, Recognizes National Prescription Drug Take Back Day

Berkshire Biomedical, Developers of COPA, Recognizes National Prescription Drug Take Back Day

Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced its support and recognition of the DEA’s National Prescription Drug Take Back Day on April 30, 2022. ...

ByBerkshire Biomedical


U.S. FDA Extends Review of Biologics License Application for REGEN-COV (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19

U.S. FDA Extends Review of Biologics License Application for REGEN-COV (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19

The company is progressing investigational next generation antibodies that are active against the currently circulating variants of concern, and has initiated a first-in-human clinical trial of one of these next generation antibodies. The development and manufacturing of REGEN-COV have been funded in part with federal funds from the Biomedical Advanced Research ...

ByRegeneron Pharmaceuticals Inc.


Antimicrobial Resistance Diagnostic Challenge Semifinalist

Antimicrobial Resistance Diagnostic Challenge Semifinalist

Affinity Biosensors Ultra-Rapid Phenotypical AST by Microbe Mass Measurement has been selected as a Step 1 semifinalist in the Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for ...

ByAffinity Biosensors


Visby Medical Executes Contract Option with BARDA for $25.5M to Develop Rapid Flu-COVID PCR Test Designed for At-Home Use

Visby Medical Executes Contract Option with BARDA for $25.5M to Develop Rapid Flu-COVID PCR Test Designed for At-Home Use

Visby Medical™, a leading medical diagnostic company, today announced that it has received an additional $25.5M in federal funding to develop and validate an at-home combination Flu-Covid test from the Biomedical Advanced Research and Development Authority (BARDA).The developmental-stage Flu-COVID PCR Test is a single-use, handheld, ...

ByVisby Medical, Inc.


Synergy Biomedical Launches BIOSPHERE® Flex SP Extremities, Synthetic Bioactive Bone Graft.

Synergy Biomedical Launches BIOSPHERE® Flex SP Extremities, Synthetic Bioactive Bone Graft.

Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® FLEX SP EXTREMITIES, Synthetic Bioactive Bone Graft. ...

BySynergy Biomedical, LLC


LightDeck Diagnostics Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022

LightDeck Diagnostics Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022

In 2021, LightDeck received a $35M grant from the Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), to increase manufacturing capacity of the company’s COVID-19 tests following $5.65M in funding from the Biomedical Advanced Research and Development Authority (BARDA) for test development. ...

ByLightDeck Diagnostics


Berkshire Biomedical, Developers of COPA,  Featured as a 2022 Top Texas Tech Startup in StartupCity Magazine

Berkshire Biomedical, Developers of COPA, Featured as a 2022 Top Texas Tech Startup in StartupCity Magazine

Berkshire Biomedical Corporation (“Berkshire” or “the Company”) is focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness. ...

ByBerkshire Biomedical


Synergy Biomedical Launches BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System

Synergy Biomedical Launches BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System

Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System. ...

BySynergy Biomedical, LLC


Cellphire Therapeutics Names W. Allan Alexander, MD as Chief Medical Officer

Cellphire Therapeutics Names W. Allan Alexander, MD as Chief Medical Officer

“His deep experience as both a practicing clinician and clinical developer in the hemostatic space will accelerate development and support clinical adoption of our products. ...

ByCellphire Therapeutics, Inc.


Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis

Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis

Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial ...

ByCytovale Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT